---
figid: PMC5853106__nihms750071f3
figtitle: Wnt Signaling Pathway in Cancer
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
- Xenopus laevis
- Lareunionomyces loeiensis
- Mouse mammary tumor virus
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
- Xenopus laevis
- Danio rerio
pmcid: PMC5853106
filename: nihms750071f3.jpg
figlink: /pmc/articles/PMC5853106/figure/F3/
number: F3
caption: This figure summarizes the different Wnt pathway modulators with variable
  specificities and at different stages of development (fully described in the main
  text). The current agents in clinical trials are the porcupine inhibitor LGK974,
  which inhibits Wnt posttranslational palmitoylation and secretion. OMP18R5, is a
  fully humanized monoclonal antibody specifically binding to multiple Frizzled (Fzd)
  receptors and OMP-54F28 is a Fc fusion protein with Fzd8, which binds all Wnt ligands.
  Both inhibit the intracellular transduction of the Wnt signal. PRI-724 specifically
  targets the β-catenin transcriptional co-activator CBP thereby blocking their interaction.
  UC-961 (cirmtuzumab) is a humanized antibody targeting the targeting specifically
  the Wnt receptor ROR1. Arrows indicate activation/induction, blunt ended lines indicate
  inhibition/blockade.
papertitle: The Wnt Signaling Pathway in Cancer.
reftext: Yann Duchartre, et al. Crit Rev Oncol Hematol. ;99:141-149.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9521498
figid_alias: PMC5853106__F3
figtype: Figure
redirect_from: /figures/PMC5853106__F3
ndex: 78de0e6f-deef-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5853106__nihms750071f3.html
  '@type': Dataset
  description: This figure summarizes the different Wnt pathway modulators with variable
    specificities and at different stages of development (fully described in the main
    text). The current agents in clinical trials are the porcupine inhibitor LGK974,
    which inhibits Wnt posttranslational palmitoylation and secretion. OMP18R5, is
    a fully humanized monoclonal antibody specifically binding to multiple Frizzled
    (Fzd) receptors and OMP-54F28 is a Fc fusion protein with Fzd8, which binds all
    Wnt ligands. Both inhibit the intracellular transduction of the Wnt signal. PRI-724
    specifically targets the β-catenin transcriptional co-activator CBP thereby blocking
    their interaction. UC-961 (cirmtuzumab) is a humanized antibody targeting the
    targeting specifically the Wnt receptor ROR1. Arrows indicate activation/induction,
    blunt ended lines indicate inhibition/blockade.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Lrp6
  - Lrp5
  - Ryk
  - Dvl1
  - Apc
  - Axin1
  - Csnk1a1
  - Ctnnb1
  - Tria1
  - Ep300
  - Crebbp
  - Pag1
  - Cytip
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - LRP6
  - LRP5
  - LINC-ROR
  - ROR1
  - ROR2
  - RYK
  - SLC7A6OS
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - IFT81
  - APC
  - PROC
  - AXIN1
  - AXIN2
  - CSNK1A1
  - CTNNB1
  - EP300
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - Wnt2
  - Wnt5
  - Wnt4
  - wg
  - fz
  - arr
  - Ror
  - Tnks
  - dsh
  - Apc2
  - Axn
  - Fs(3)Apc
  - CkIalpha
  - arm
  - pg
  - osa
  - nej
  - CBP
  - eIF4E1
  - lrp6.L
  - lrp6.S
  - lrp5.L
  - ryk.S
  - dvl2.L
  - dvl2.S
  - apc.L
  - axin1.S
  - ctnnb1.S
  - ctnnb1.L
  - crebbp.S
  - crebbp.L
  - ep300.L
  - ep300.S
  - lrp6
  - lrp5
  - ryk
  - apc
  - csnk1a1
  - cax1
  - cax2
  - ctnnb1
  - Arachidonic acid
  - Sulindac
---
